Illumina's margin expansion and a coming revenue recovery should help the stock multiples re-rate toward life science ...

Sequencing giant Illumina Inc. ILMN is set to release third-quarter 2024 results on Nov. 4 after the closing bell. Stay up-to ...

Illumina’s strategic initiatives include the launch of the MiSeq i100 Series, a new benchtop sequencer aimed at accelerating genomic innovation. The company has also announced plans to expand its ...

SAN DIEGO, Oct. 24, 2024 /PRNewswire/ -- Illumina, Inc. (NASDAQ: ILMN), a global leader in DNA sequencing and array-based technologies, today unveiled its MiSeq™ i100 Series of sequencing ...

In addition, recent advancements for its MiSeq i100 Series sequencing instrument have helped Illumina strengthen its foothold in the industry. During this quarter, Illumina made strides despite ...

New generation sequencers, like Illumina's MiSeq devices, help determine the sequence of DNA or RNA to study genetic ...

While Illumina maintains a strong position in the sequencing market, the company faces increasing competitive pressures. The introduction of new products, such as the MiSeq i100 series ...

SAN DIEGO, Oct. 9, 2024 /PRNewswire/ -- Illumina, Inc. (NASDAQ: ILMN), a global leader in DNA sequencing and array-based technologies, today unveiled its MiSeq™ i100 Series of sequencing systems, ...

While Illumina maintains a strong position in the sequencing market, the company faces increasing competitive pressures. The introduction of new products, such as the MiSeq i100 series, is seen as a ...